Advancement of novel RNA Therapeutic will leverage Enzymatic Synthesis Platform from EnPlusOne .

The agreement covers multi-disciplinary efforts to develop a diseaseagnostic novel RNA therapeutic with the potential to treat diverse diseases , including types of cancer and infectious diseases – and to be effectively and rapidly deployable .

Initially , up to US $ 3.5 million of the agreement is focused on the EnPlusOne enzymatic platform .

ARPA-H is a federal funding agency which funds transformative biomedical and health research breakthroughs , translating prioritised research from the lab to applications in the marketplace .

The ARPA-H award will allow the Wyss Institute team to significantly accelerate and expand efforts to advance the therapy towards an Investigational New Drug ( IND ) submission to the Federal Food and Drug Administration ( FDA ).

The team is initially focusing on cancer and will explore the platform ’ s potential for difficult-to-treat infectious diseases .

The ARPA-H project will build on a newly developed Duplex RNA technology and leverage the powerful RNA delivery capabilities developed by groups at the Wyss Institute , along with the groundbreaking enzymatic RNA synthesis capabilities of EnPlusOne to optimise the RNA ’ s design and scalability .

Dan Ahlstedt , Co-founder and Chief Operating Officer , EnPlusOne Biosciences , said : “ We come full circle rejoining our Wyss colleagues for this exciting collaboration . This comprehensive programme will give us the opportunity to demonstrate how enabling modifications and limitless scale can be unlocked by our ezRNA platform . We are grateful to the Wyss Institute and ARPA-H for recognising the current problems facing RNA manufacturing and sharing our vision that an enzymatic approach is the future . We look forward to progressing our platform alongside this team as we collectively work to address critical human health challenges .”

www . intelligenthealth . tech 63